← Back to Search

mHealth Texting Tool for Type 2 Diabetes

N/A
Recruiting
Led By Antoinette Schoenthaler, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient Inclusion Criteria: Have a diagnosis of T2D for ≥6 months; Have uncontrolled T2D defined as HbA1c >7% documented in the EHR on at least two visits in the past year; Fluency in English or Spanish; Be willing to send/receive text messages;
Primary Care Provider Inclusion Criteria: Fulltime primary care provider (MD/DO, NP) practicing at the participating family health centers (FHCs) and, Provide care to at least five patients with a diagnosis of T2D.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial will test a new mobile platform, MJS DIABETES, which uses text-messaging to capture patients' self-reported PROs in real-time. The platform will be integrated into the EHR system, the primary care practice and the lives of patients with T2D. A randomized control trial will be used to identify the efficacy of MJS DIABETES versus Usual Care (UC) on reduction HbA1c at 12-months, among 282 patients with T2D who receive care in safety-net practices.

Who is the study for?
This trial is for adults with type 2 diabetes who have had uncontrolled blood sugar levels (HbA1c >7%) over the past year, can communicate in English or Spanish, and are willing to send/receive text messages. Their primary care providers must work full-time at certain health centers and see at least five patients with type 2 diabetes.Check my eligibility
What is being tested?
The study tests MJS DIABETES, a mobile platform that uses texting to collect patient-reported data on their condition, provides motivational feedback, and integrates this information into electronic health records for better management of type 2 diabetes compared to usual care.See study design
What are the potential side effects?
Since MJS DIABETES involves non-invasive technology use rather than medication or medical procedures, traditional side effects are not applicable. However, participants may experience issues related to privacy concerns or stress from regular communication.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had type 2 diabetes for over 6 months, my HbA1c level is above 7%, I speak English or Spanish, and I am okay with texting.
Select...
I am a full-time primary care provider at a participating FHC and treat at least 5 patients with type 2 diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
reduction in the levels of HbA1c

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MJS DIABETESExperimental Treatment1 Intervention
will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
Group II: Usual CareActive Control1 Intervention
Standard Diabetes Treatment

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,362 Previous Clinical Trials
817,421 Total Patients Enrolled
Antoinette Schoenthaler, MDPrincipal InvestigatorNYU Langone Health
1 Previous Clinical Trials
26 Total Patients Enrolled

Media Library

MJS Diabetes Clinical Trial Eligibility Overview. Trial Name: NCT03652389 — N/A
Type 2 Diabetes Research Study Groups: MJS DIABETES, Usual Care
Type 2 Diabetes Clinical Trial 2023: MJS Diabetes Highlights & Side Effects. Trial Name: NCT03652389 — N/A
MJS Diabetes 2023 Treatment Timeline for Medical Study. Trial Name: NCT03652389 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this investigation recruiting senior citizens?

"According to the inclusivity conditions, individuals between 18 and 90 years of age can participate. In comparison, there exist 184 trials for minors and 897 clinical studies available for seniors."

Answered by AI

To whom is this experimental procedure available?

"This clinical trial requires 346 participants with type 2 diabetes who are aged 18 to 90. The key criteria for applicants include: being a full-time primary care provider, providing medical services to at least 5 patients diagnosed with Type 2 Diabetes (T2D), having had the diagnosis of T2D for 6 months or more, displaying an HbA1c level greater than 7% in their Electronic Health Record on two separate occasions within a year, fluency in either English or Spanish and lastly agreement to send/receive text messages."

Answered by AI

Are there any open slots available for participants in this experiment?

"Affirmative, records from clinicaltrials.gov show that this experiment is actively seeking new participants and has been since it was initially published on December 18th 2018. Of the 346 desired patients, they will all be recruited from a single location."

Answered by AI

How many test subjects are included in this medical experiment?

"Affirmative, the information available on clinicaltrials.gov shows that this medical trial is currently recruiting individuals for participation. It was originally posted on December 18th 2018 and has since been updated as recently as August 25th 2022. 346 participants must be recruited from a single site."

Answered by AI
~16 spots leftby Jun 2024